Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges
As a ubiquitous human pathogen, the Epstein–Barr virus (EBV) has established lifelong persistent infection in about 95% of the adult population. The EBV infection is associated with approximately 200,000 human cancer cases and 140,000 deaths per year. The presence of EBV in tumor cells provides a un...
Saved in:
Main Authors: | Febri Gunawan Sugiokto, Renfeng Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/17/1/110 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The probable progression of Epstein-Barr virus (EBV) to chronic active EBV/reactivation weakens the immune response and stimulates Cryptococcus neoformans infection, which invariably proves fatal: a case report and review of the literature
by: Gargee Mishra, et al.
Published: (2025-01-01) -
基于episomal CRISPR/Cas9 载体的基因敲入方法
by: 邹征伟, et al.
Published: (2018-01-01) -
A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection
by: Ping Li, et al.
Published: (2025-01-01) -
Corrigendum: A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection
by: Ping Li, et al.
Published: (2025-02-01) -
Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer
by: Liying Sun, et al.
Published: (2025-01-01)